Ticlopidine enhances the platelet inhibitory capacity of abciximab in vitro.

This publication has 31 references indexed in Scilit:

• Pharmacokinetics and Effect of Ticlopidine on Platelet Aggregation in Subjects with Normal and Impaired Renal Function
  The Journal of Clinical Pharmacology, 1997
• Hemostaseologic and Hematologic Parameters with Aspirin and Ticlopidine Treatment in Patients with Cerebrovascular Disease: A Cross-Over Study
  Journal of Cardiovascular Pharmacology, 1996
• Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors
  Journal of the American College of Cardiology, 1995
• Effect of plasma fibrinogen concentration on the inhibition of platelet aggregation after ticlopidine compared with aspirin.
  Stroke, 1994
• Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months
  The Lancet, 1994
• Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection.
  Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992
• Domains specifying thrombin–receptor interaction
  Nature, 1991
• Pharmacology of Ticlopidine: A Review
  Seminars in Thrombosis and Hemostasis, 1989
• Functionally thrombasthenic state in normal platelets following the administration of ticlopidine.
  Journal of Clinical Investigation, 1985
• Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal
  Nature, 1962